Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/anti-CD3 bispecific antibody MBS303

A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3 bispecific antibody MBS303 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity of T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD20/CD3 bispecific antibody MBS303
anti-CD20/CD3 monoclonal antibody MBS303
anti-CD3/anti-CD20 monoclonal antibody MBS303
T-cell engager MBS303
TCE MBS303
Code name:MB S303
MB-S303
MBS303
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search